Researchers have engineered a probiotic bacterium capable of detecting high glucose levels and automatically producing GLP-1, a hormone used to treat diabetes and obesity. The system, called GIFT, was developed using a modified strain of Escherichia coli Nissle 1917 and demonstrated improved glycemic control and metabolic parameters in animal models, according to a study published in Nature reported by MondoSanità.
GIFT system uses synthetic biology to trigger GLP-1 production
The GIFT system transforms a well-known probiotic, Escherichia coli Nissle 1917, into a programmable biological factory. Researchers inserted a genetic circuit that functions as a molecular switch. When glucose levels rise, the bacterium’s metabolism triggers a signal through the HexT protein, activating the genes required to produce GLP-1. Once the glucose signal decreases, the circuit shuts down.
Unlike standard engineered bacteria that produce molecules at a constant rate, this “sense-and-respond” system only releases the therapeutic molecule in response to specific biological signals. To ensure the probiotic survives the journey through the gastrointestinal tract, scientists applied a protective coating made of poloxamer and tannic acid, which extends the bacterium’s activity in the gut, MondoSanità reported.
Animal trials show metabolic improvements and lean mass retention
In preclinical tests detailed in Nature, the GIFT system attenuated glucose spikes following ingestion. Long-term treatments in diabetic animal models resulted in improved insulin resistance, better glucose regulation, and positive changes in lipid parameters and fat mass.
The study compared the results of GIFT against semaglutide.
Living therapeutics shift the approach to microbiota
This research moves beyond traditional probiotics intended to make the gut “healthier” and enters the field of living therapeutics. By using synthetic biology, the intestine becomes a temporary environment for programmed microorganisms to perform a precise medical function.
Clinical hurdles remain before human application
The transition from animal models to human patients requires significant verification. Researchers must still determine the stability of the genetic circuit, the duration of the bacteria’s stay in the human gut, and how the engineered strain interacts with the complex human microbiota.
Common questions about the GIFT probiotic research
Is this a natural alternative to Ozempic?
No. While it produces the same hormone (GLP-1), it is a genetically engineered living therapy, not a natural supplement. It remains in the preclinical research phase and is not available for human use.
How does the bacteria know when to release the hormone?
The bacteria use a genetic circuit tied to the HexT protein. This protein acts as a sensor that detects increased glucose in the environment, which then flips the “switch” to start GLP-1 production.
Why is the protective coating necessary?
The gastrointestinal tract is a harsh environment. The tannic acid and poloxamer coating protects the E. coli Nissle 1917 strain, allowing it to survive longer and remain active in the intestines.
The GIFT system allows doctors to use the microbiota as a programmable tool for real-time disease management rather than just studying it.
Keep reading